JP7349786B2 - Cns浮腫に関連する損傷または状態を処置する方法 - Google Patents
Cns浮腫に関連する損傷または状態を処置する方法 Download PDFInfo
- Publication number
- JP7349786B2 JP7349786B2 JP2018517841A JP2018517841A JP7349786B2 JP 7349786 B2 JP7349786 B2 JP 7349786B2 JP 2018517841 A JP2018517841 A JP 2018517841A JP 2018517841 A JP2018517841 A JP 2018517841A JP 7349786 B2 JP7349786 B2 JP 7349786B2
- Authority
- JP
- Japan
- Prior art keywords
- subject
- hours
- composition
- sur1
- edema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238461P | 2015-10-07 | 2015-10-07 | |
| US62/238,461 | 2015-10-07 | ||
| PCT/US2016/055988 WO2017062765A1 (en) | 2015-10-07 | 2016-10-07 | Methods of treating injuries or conditions related to cns edema |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021022562A Division JP2021073317A (ja) | 2015-10-07 | 2021-02-16 | Cns浮腫に関連する損傷または状態を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018530564A JP2018530564A (ja) | 2018-10-18 |
| JP2018530564A5 JP2018530564A5 (cg-RX-API-DMAC7.html) | 2019-11-14 |
| JP7349786B2 true JP7349786B2 (ja) | 2023-09-25 |
Family
ID=58488580
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517841A Active JP7349786B2 (ja) | 2015-10-07 | 2016-10-07 | Cns浮腫に関連する損傷または状態を処置する方法 |
| JP2021022562A Withdrawn JP2021073317A (ja) | 2015-10-07 | 2021-02-16 | Cns浮腫に関連する損傷または状態を処置する方法 |
| JP2023020327A Active JP7592768B2 (ja) | 2015-10-07 | 2023-02-13 | Cns浮腫に関連する損傷または状態を処置する方法 |
| JP2024142687A Active JP7810762B2 (ja) | 2015-10-07 | 2024-08-23 | Cns浮腫に関連する損傷または状態を処置する方法 |
| JP2026009068A Pending JP2026069546A (ja) | 2015-10-07 | 2026-01-22 | Cns浮腫に関連する損傷または状態を処置する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021022562A Withdrawn JP2021073317A (ja) | 2015-10-07 | 2021-02-16 | Cns浮腫に関連する損傷または状態を処置する方法 |
| JP2023020327A Active JP7592768B2 (ja) | 2015-10-07 | 2023-02-13 | Cns浮腫に関連する損傷または状態を処置する方法 |
| JP2024142687A Active JP7810762B2 (ja) | 2015-10-07 | 2024-08-23 | Cns浮腫に関連する損傷または状態を処置する方法 |
| JP2026009068A Pending JP2026069546A (ja) | 2015-10-07 | 2026-01-22 | Cns浮腫に関連する損傷または状態を処置する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20180280325A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3359162B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP7349786B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20240105519A (cg-RX-API-DMAC7.html) |
| CN (2) | CN108348534A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2016335767B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018006925A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3001321A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201890893A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2940669T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1257542A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL258509B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA45574A (cg-RX-API-DMAC7.html) |
| MX (1) | MX392466B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017062765A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104602682B (zh) | 2012-05-08 | 2018-12-14 | 埃罗米克斯公司 | 用于治疗水通道蛋白介导的疾病的化合物 |
| EP3065729A4 (en) | 2013-11-06 | 2017-05-31 | Aeromics, Inc. | Novel formulations |
| KR20240105519A (ko) * | 2015-10-07 | 2024-07-05 | 레메디 파마슈티칼즈, 인크. | Cns 부종과 관련한 손상 또는 병태의 치료 방법 |
| WO2020041905A1 (en) * | 2018-08-31 | 2020-03-05 | The University Of British Columbia | Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds |
| JP2022531312A (ja) * | 2019-05-02 | 2022-07-06 | バイオジェン チェサピーク エルエルシー | 中枢神経系挫傷に苦しむ対象の治療方法 |
| CN120004770A (zh) * | 2020-07-17 | 2025-05-16 | 上海森辉医药有限公司 | 磺酰脲类衍生物及其医药用途 |
| US12251389B1 (en) | 2024-04-22 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212154A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
| WO2025212189A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor |
| WO2025212155A1 (en) * | 2024-04-05 | 2025-10-09 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor |
| US12251388B1 (en) * | 2024-05-09 | 2025-03-18 | Remedy Pharmaceuticals, Inc. | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005534285A (ja) | 2002-03-20 | 2005-11-17 | ユニバーシティ・オブ・メリーランド, ボルティモア | 神経細胞の非選択的陽イオンチャネルおよび脳腫脹を治療する方法 |
| JP2013532658A (ja) | 2010-07-19 | 2013-08-19 | レメディー ファーマシューティカルズ, インコーポレイテッド | グリブリドおよび他の薬剤の静脈内投与方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856360A (en) | 1996-05-03 | 1999-01-05 | Children's Hospital Medical Center | Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock |
| US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| US20050246000A1 (en) * | 2004-05-03 | 2005-11-03 | Seacoast Technologies, Inc. | Cooled craniectomy |
| CA2691199C (en) | 2007-06-22 | 2017-09-12 | Marc J. Simard | Inhibitors of ncca-atp channels for therapy |
| CA3123813C (en) * | 2007-12-04 | 2024-10-08 | Remedy Pharmaceuticals, Inc. | IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS |
| KR20240105519A (ko) | 2015-10-07 | 2024-07-05 | 레메디 파마슈티칼즈, 인크. | Cns 부종과 관련한 손상 또는 병태의 치료 방법 |
-
2016
- 2016-10-07 KR KR1020247021781A patent/KR20240105519A/ko not_active Ceased
- 2016-10-07 MX MX2018004286A patent/MX392466B/es unknown
- 2016-10-07 EP EP16854422.9A patent/EP3359162B1/en active Active
- 2016-10-07 AU AU2016335767A patent/AU2016335767B2/en active Active
- 2016-10-07 CN CN201680066630.6A patent/CN108348534A/zh active Pending
- 2016-10-07 BR BR112018006925A patent/BR112018006925A2/pt not_active Application Discontinuation
- 2016-10-07 WO PCT/US2016/055988 patent/WO2017062765A1/en not_active Ceased
- 2016-10-07 US US15/763,932 patent/US20180280325A1/en not_active Abandoned
- 2016-10-07 IL IL258509A patent/IL258509B2/en unknown
- 2016-10-07 JP JP2018517841A patent/JP7349786B2/ja active Active
- 2016-10-07 HK HK18116503.6A patent/HK1257542A1/zh unknown
- 2016-10-07 EA EA201890893A patent/EA201890893A1/ru unknown
- 2016-10-07 KR KR1020187012950A patent/KR102681027B1/ko active Active
- 2016-10-07 MA MA045574A patent/MA45574A/fr unknown
- 2016-10-07 CN CN202211412393.8A patent/CN115737816A/zh active Pending
- 2016-10-07 KR KR1020267018914A patent/KR20260093449A/ko active Pending
- 2016-10-07 ES ES16854422T patent/ES2940669T3/es active Active
- 2016-10-07 CA CA3001321A patent/CA3001321A1/en active Pending
-
2021
- 2021-02-16 JP JP2021022562A patent/JP2021073317A/ja not_active Withdrawn
- 2021-09-29 US US17/488,591 patent/US11951085B2/en active Active
-
2022
- 2022-11-28 AU AU2022279369A patent/AU2022279369B2/en active Active
-
2023
- 2023-02-13 JP JP2023020327A patent/JP7592768B2/ja active Active
-
2024
- 2024-03-04 US US18/595,205 patent/US20240216309A1/en active Pending
- 2024-08-23 JP JP2024142687A patent/JP7810762B2/ja active Active
- 2024-09-30 US US18/902,504 patent/US20250017880A1/en active Pending
-
2025
- 2025-04-14 AU AU2025202620A patent/AU2025202620A1/en not_active Abandoned
-
2026
- 2026-01-22 JP JP2026009068A patent/JP2026069546A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005534285A (ja) | 2002-03-20 | 2005-11-17 | ユニバーシティ・オブ・メリーランド, ボルティモア | 神経細胞の非選択的陽イオンチャネルおよび脳腫脹を治療する方法 |
| JP2013532658A (ja) | 2010-07-19 | 2013-08-19 | レメディー ファーマシューティカルズ, インコーポレイテッド | グリブリドおよび他の薬剤の静脈内投与方法 |
Non-Patent Citations (3)
| Title |
|---|
| Nature Medicine, 2006, Vol.12 No.4 p.433-440 |
| Neurocrit Care,2014 Aug., Vol.21,p.43-51 |
| Trans.Stroke.Res.,2012,Vol.3,p.286-295 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7592768B2 (ja) | Cns浮腫に関連する損傷または状態を処置する方法 | |
| Liotta | Management of cerebral edema, brain compression, and intracranial pressure | |
| JP2018530564A5 (cg-RX-API-DMAC7.html) | ||
| Nivatpumin et al. | Ephedrine versus ondansetron in the prevention of hypotension during cesarean delivery: a randomized, double-blind, placebo-controlled trial | |
| Armstrong et al. | Phenytoin and fosphenytoin: a model of cost and clinical outcomes | |
| AL-Morsy et al. | Effect of adding nalbuphine hydrochloride versus fentanyl on the characteristic of hyperbaric bupivacaine spinal block for lower limb orthopedic surgery | |
| US20220226353A1 (en) | Method for treating subjects suffering from central nervous system contusions | |
| US20260115210A1 (en) | Method for treating subjects suffering from central nervous system contusions | |
| JP5509085B2 (ja) | 血栓溶解についての新規な患者亜群 | |
| Shannon et al. | An intravenous fluid bolus is not necessary before administration of intrathecal fentanyl for labor analgesia | |
| Soramo et al. | Effectiveness of Prophylactic Bolus Phenylephrine on the Prevention of Postspinal Hypotension During Elective Cesarean Section at Gandhi Memorial Hospital, Ethiopia 2024, Observational Prospective Cohort Study | |
| AbdelRady et al. | Role of Granisetron in preventing hypotension after spinal anaesthesia with Levobupivacaine in rheumatic patients undergoing elective cesarean section: A randomized controlled trial | |
| Ansari et al. | Intravenous Bolus Phenylephrine and Intravenous Bolus Norepinephrine for Treatment of Maternal Hypotension in Spinal Anesthesia During Cesarean Section: A Prospective, Randomized, Comparative Study | |
| Bondok et al. | The equisedative effect of dexmedetomidine versus propofol on supraclavicular brachial plexus block and recovery profile in patients with ischemic heart disease. | |
| JP2011500617A5 (cg-RX-API-DMAC7.html) | ||
| Murthy et al. | Attenuating emergence response: Fentanyl or dexmedetomidine, which is better? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191004 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191004 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201005 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210216 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210715 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211112 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211112 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20211206 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211207 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20211224 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20211228 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20221114 |
|
| C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20221219 |
|
| C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20221219 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230301 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230619 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230912 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7349786 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |